Latest News and Press Releases

ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to...

Castle presented new data from the first independent validation of the recently published COOG2.1 study by Harbour et al. at ARVO 2025.

Alkeus Pharmaceuticals presents gildeuretinol data during the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025

Alkeus Pharmaceuticals announces presentations of gildeuretinol data in Stargardt and GA during ARVO May 4-8

PASADENA, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, announced that more than 25 of its scientists and...

Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following...

- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector® Provides Targeted and Compartmentalized Delivery of Therapeutics...

New York, Jan. 23, 2025 (GLOBE NEWSWIRE) -- A groundbreaking study published in the January edition of Translational Vision Science & Technology, an ARVO journal, reveals that individuals with...

PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US    Symptoms often start in childhood leading to blindness by midlife with no approved...

Alkeus Pharmaceuticals announces interim data demonstrating no signs of disease progression in early-stage Stargardt patients treated with gildeuretinol.